Large drugmakers with the lowest PE ratio

Ranked

41

of 412 large drugmakers we cover

Median

18.5×

Lowest

3.7×

CRMD

Range

3.7× to 204×

#	Company	PE	PE vs its 10 years	Revenue growth (TTM)	Market cap
1	CRMDCorMedix	3.7×	26th pct	+280.5%	$611.9M
2	ATNMActinium Pharmaceuticals	4.2×	n/a	n/m	$47.8M
3	IRWDIronwood Pharmaceuticals	4.5×	0th pct	+26.2%	$571.7M
4	ABUSArbutus Biopharma	5.4×	n/a	n/m	$831M
5	SPROSpero Therapeutics	10.1×	52nd pct	−3.3%	$64.6M
6	ZVRAZevra Therapeutics	10.5×	n/a	+119.4%	$582.6M
7	ANABAnaptysbio	10.7×	n/a	n/m	$1.5B
8	OMEROmeros	10.9×	n/a	n/m	$1.2B
9	NRIXNurix Therapeutics	11.0×	n/a	n/m	$2.8B
10	HRMYHarmony Biosciences	11.7×	24th pct	+24.3%	$2.1B
11	NATRNatures Sunshine Products	12.0×	6th pct	+6.8%	$213.8M
12	INDVIndivior Pharmaceuticals	12.4×	2nd pct	+13.5%	$4.1B
13	PBHPrestige Consumer Healthcare	13.4×	28th pct	−1.4%	$2.3B
14	BMYBristol-Myers Squibb	13.5×	10th pct	+3.1%	$125.6B
15	JAZZJazz Pharmaceuticals	14.6×	15th pct	+12.6%	$13.9B
16	LFVNLifevantage	14.7×	30th pct	−20.1%	$73.4M
17	AMPHAmphastar Pharmaceuticals	14.8×	25th pct	+1.0%	$1.1B
18	ANIPANI Pharmaceuticals	15.4×	2nd pct	+30.9%	$1.7B
19	PAHCPhibro Animal Health	15.9×	20th pct	+17.1%	$1.6B
20	OGNOrganon	17.9×	97th pct	−2.5%	$3.6B
21	COLLCollegium Pharmaceutical	18.5×	46th pct	+14.3%	$747.5M
22	TGTXTG Therapeutics	19.8×	57th pct	+76.1%	$8.3B
23	PBYIPuma Biotechnology	21.2×	82nd pct	−2.9%	$568.9M
24	AMGNAmgen	27.3×	79th pct	+9.1%	$237.5B
25	LQDALiquidia	30.7×	n/a	n/m	$3.8B
26	LGNDLigand Pharmaceuticals	32.3×	41st pct	+54.9%	$6.1B
27	PFEPfizer	39.5×	98th pct	−0.2%	$171.2B
28	JNJJohnson & Johnson	40.0×	90th pct	+7.8%	$635.8B
29	AMRXAmneal Pharmaceuticals	41.6×	32nd pct	+9.3%	$6.5B
30	LLYEli Lilly and	42.7×	52nd pct	+49.6%	$1.2T
31	BIIBBiogen	44.4×	100th pct	+0.3%	$37B
32	ARVNArvinas	45.6×	n/a	−15.0%	$477.3M
33	KNSAKiniksa Pharmaceuticals International	79.1×	37th pct	+58.9%	$6B
34	ABBVAbbVie	80.7×	88th pct	+10.4%	$504.8B
35	PCRXPacira BioSciences	104×	68th pct	+5.7%	$1.5B
36	ALKSAlkermes plc.	115×	95th pct	+10.8%	$7.3B
37	MRKMerck	116×	93rd pct	+4.6%	$358.4B
38	PTGXProtagonist Therapeutics	134×	81st pct	+34.8%	$9B
39	ARQTArcutis Biotherapeutics	142×	n/a	+76.1%	$3.9B
40	BMRNBiomarin Pharmaceutical	151×	69th pct	+11.2%	$10.8B
41	CORTCorcept Therapeutics	204×	94th pct	+16.0%	$9.3B

Not ranked: 288 with a loss over the last year, 20 with a quarter missing, 11 with not a meaningful number. 52 companies whose data behind this number has a caveat are left out until it is checked.

A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.